• Citer

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: Insights from BOLERO-2

par Rugo, Hope;Pritchard, Kathleen;Gnant, Michael;Noguchi, Shinzaburo;Piccart-Gebhart, Martine ;Hortobagyi, Gabriel N.;Baselga, José;Perez, Alejandra;Geberth, Matthias;Csöszi, Tibor;Chouinard, Edmond;Srimuninnimit, Vichien;Puttawibul, Puttisak;Eakle, Janice;Feng, Wentao;El-Hashimy, Mona;Taran, Tetiana;Bauly, Hounayda;Burris, Howard H.A.
Référence Annals of oncology, 25, 4, page (808-815), mdu009
Publication Publié, 2014

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: Insights from BOLERO-2
Auteur:	Rugo, Hope; Pritchard, Kathleen; Gnant, Michael; Noguchi, Shinzaburo; Piccart-Gebhart, Martine; Hortobagyi, Gabriel N.; Baselga, José; Perez, Alejandra; Geberth, Matthias; Csöszi, Tibor; Chouinard, Edmond; Srimuninnimit, Vichien; Puttawibul, Puttisak; Eakle, Janice; Feng, Wentao; El-Hashimy, Mona; Taran, Tetiana; Bauly, Hounayda; Burris, Howard H.A.
Informations sur la publication:	Annals of oncology, 25, 4, page (808-815), mdu009
Statut de publication:	Publié, 2014
Sujet CREF:	Hématologie
	Cancérologie
Mots-clés:	Advanced breast cancer
	Everolimus
	Mammalian target of rapamycin (mTOR)
	Safety
MeSH keywords:	Adult
	Aged
	Aged, 80 and over
	Breast Neoplasms -- drug therapy -- genetics -- pathology
	Disease-Free Survival
	Drug-Related Side Effects and Adverse Reactions -- classification -- pathology
	Female
	Humans
	Middle Aged
	Neoplasm Staging
	Postmenopause
	Sirolimus -- administration & dosage -- adverse effects -- analogs & derivatives
	TOR Serine-Threonine Kinases -- genetics
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdu009
	info:pii/mdu009
	info:scp/84897102034
	info:pmid/24615500
	PMC3969554